For male patients, updated recommendations are that either the male patient or his female partner use reliable contraception during mycophenolate treatment and for at least 90 days after stopping treatment.
For female patients, the risk is unchanged. Mycophenolate must not be used in pregnant women unless there are no suitable alternatives to prevent transplant rejection. In addition, female patients who can become pregnant must use at least one reliable form of contraception before, during and for 6 weeks after stopping treatment. Two forms of contraception are preferred.